MedPage Today) — Adding a monoclonal antibody approved for blood cancer indications to standard therapy for adults with active lupus nephritis outperformed standard therapy alone in a phase III trial.
In the REGENCY study, 46.4% of patients…
We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue
You cannot copy content of this app
Woww